Can a GLP-1 lower blood pressure during perimenopause?

# Can a GLP-1 lower blood pressure during perimenopause?

If your blood pressure has crept up in your forties or fifties, that is a common and biologically real part of the menopause transition, not a personal failing. It is a fair question whether a weight medicine might help those numbers. The honest answer is that these medicines tend to nudge blood pressure in the right direction, but that movement rides largely on weight loss, and they are not blood pressure drugs. This piece walks through what shifts in midlife, what the trials actually measured, and where the evidence is solid versus where it is a reasonable extrapolation.

Key takeaways

Dr. Linda's take

Patients bring me a blood pressure reading before they bring me a symptom, and in midlife the reading has often drifted up on its own. I try to normalize that first, because it is not a discipline problem. The vascular system in these years is responding to a hormonal shift, and that shift is measurable across women, which tells me it is biology.

So when someone asks whether one of these medicines will fix her blood pressure, I answer two questions at once. Do these medicines tend to improve blood pressure? Yes, modestly, in the large weight-loss trials. Were those trials designed to treat blood pressure in perimenopausal women, with a blood pressure target as the goal? No, they were not. I would rather you hold both of those than walk away with false comfort or false worry. If you want a general, no-pressure starting point, our eligibility quiz is education, not a plan for your specific readings.

Why does blood pressure change during perimenopause?

Because the loss of estrogen reaches the blood vessels, not just the scale.

Blood pressure in women is not fixed across the lifespan. Sex differences in blood pressure are evident from puberty through menopause, with premenopausal females exhibiting lower blood pressure than males. That relative protection is tied to hormones. Estrogen and its receptor signaling have beneficial effects on vascular function, including vasodilation, decreased blood pressure, and cardiovascular protection.

When that signaling fades, the cardiovascular picture shifts. Women during the menopause transition, with declining ovarian function and production of estrogen and progesterone, show a marked increase in the incidence of cardiovascular disease and associated vascular dysfunction. This is also the window when body fat redistributes, which is why we wrote about perimenopause belly fat as its own topic. The point for blood pressure is simple: rising readings in these years usually reflect the transition itself, not something you did wrong.

How does a GLP-1 affect blood pressure?

The clearest signal comes from the large obesity trials, where blood pressure was tracked as one of several cardiometabolic measures.

In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure, and diastolic blood pressure, as well as positive changes in glycated hemoglobin, C-reactive protein, and lipid levels. Pulling the program together, the summary is consistent. Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity.

There is real weight change underneath those numbers. In the STEP 1 trial, once-weekly semaglutide at 2.4 mg reduced body weight by 14.9% from baseline over 68 weeks, compared with 2.4% in the placebo group. The STEP 1 trial enrolled 1961 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes. So the blood pressure improvement is real, but notice who was studied. These were general adults with obesity, not women defined by perimenopause, and blood pressure was a secondary readout rather than the target.

Is the benefit from the medicine or from weight loss?

Mostly from the weight loss, and that distinction changes how you should read the numbers.

The magnitude of weight loss achieved with these therapies can determine the level of improvement in various comorbidities. In other words, the blood pressure movement in these trials travels with the weight change rather than appearing as a separate, direct antihypertensive effect. Long-term weight management drugs have the potential to reduce body weight and blood pressure in obese or overweight individuals. That potential is genuine, but it is a downstream benefit of losing weight, not the action of a dedicated blood pressure medicine.

The labels reflect that. According to the WEGOVY label, semaglutide is indicated to reduce excess body weight and maintain weight reduction long term, and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and it is not indicated to treat blood pressure. If the safety question is what is really on your mind first, whether these medicines are safe to start in perimenopause is the companion to this one.

What should you watch during perimenopause?

This is where general education stops and individual care begins, so I will stay on the right side of that line.

The honest limit of the evidence is worth stating plainly. A Cochrane review of weight-reducing drugs in people with hypertension included new randomized trials evaluating the recently approved drugs semaglutide and tirzepatide. In that review, the evidence for people with hypertension remained insufficient to draw conclusions regarding the benefits of pharmacological weight loss in terms of reducing the risk of mortality or cardiovascular morbidity. So the reasonable, non-prescriptive takeaway is that midlife is a sensible time to actually know your blood pressure and review it with a clinician who sees your full history. Whether any medicine belongs in that plan depends on far more than a single reading, and it is not a decision an article can make for you. Many women also ask about combining these medicines with hormone therapy in perimenopause, and about what happens to cholesterol during perimenopause.

Frequently asked questions

Does a GLP-1 lower blood pressure?

In the obesity trials it points that way rather than acting as a dedicated blood pressure drug. In STEP 1 to 3 and STEP 5, semaglutide led to greater reductions from baseline versus placebo in body weight, waist circumference, body mass index, systolic blood pressure, and diastolic blood pressure, as well as positive changes in glycated hemoglobin, C-reactive protein, and lipid levels. The magnitude of weight loss achieved with these therapies can determine the level of improvement in various comorbidities, so the blood pressure change largely follows the weight lost.

Why does blood pressure rise during perimenopause?

Because the change is tied to the loss of estrogen. Estrogen and its receptor signaling have beneficial effects on vascular function, including vasodilation, decreased blood pressure, and cardiovascular protection. Women during the menopause transition, with declining ovarian function and production of estrogen and progesterone, show a marked increase in the incidence of cardiovascular disease and associated vascular dysfunction.

Is the blood pressure benefit proven in perimenopausal women?

Not directly. The blood pressure improvements come from obesity trials in general adults. The STEP 1 trial enrolled 1961 adults with obesity, or overweight with at least one weight-related condition, who did not have diabetes, and those studies did not select or analyze participants by menopausal status. Applying the finding to a perimenopausal woman is a fair extrapolation, not a measured result.

Is a GLP-1 a treatment for high blood pressure?

No. According to the WEGOVY label, semaglutide is indicated to reduce excess body weight and maintain weight reduction long term, and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and it is not indicated to treat blood pressure. Any blood pressure improvement is a downstream effect of weight loss, and the choice of a blood pressure treatment belongs to a licensed clinician.

References

1. J Pharmacol Exp Ther (2025). Menopause-related changes in vascular signaling by sex hormones. PubMed PMID 40184819. https://pubmed.ncbi.nlm.nih.gov/40184819/ (Accessed 2026-07-26).
2. Annu Rev Physiol (2026). Novel Advances in Our Understanding of Sex-Dependent Control of Blood Pressure. PubMed PMID 40896847. https://pubmed.ncbi.nlm.nih.gov/40896847/ (Accessed 2026-07-26).
3. Postgrad Med (2022). Cardiometabolic risk factors efficacy of semaglutide in the STEP program. PubMed PMID 36691308. https://pubmed.ncbi.nlm.nih.gov/36691308/ (Accessed 2026-07-26).
4. N Engl J Med (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed PMID 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ (Accessed 2026-07-26).
5. Cochrane Database Syst Rev (2026). Long-term effects of weight-reducing drugs in people with hypertension. PubMed PMID 42318855. https://pubmed.ncbi.nlm.nih.gov/42318855/ (Accessed 2026-07-26).
6. DailyMed. WEGOVY (semaglutide) label, Indications and Usage. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-26).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-26.*